Company profile: Monopar Therapeutics
1.1 - Company Overview
Company description
- Provider of orphan oncology therapeutics development, including MNPR-101-Zr, an imaging agent for MNPR-101 RIT in Phase 1 clinical trials; MNPR-101 RIT, a treatment for advanced solid cancers in late preclinical development; and drug candidates for solid cancers in early preclinical development.
Products and services
- MNPR-101 RIT: Late preclinical-stage treatment for advanced solid cancers, coordinated with MNPR-101-Zr imaging agent, developed specifically alongside
- MNPR-101-Zr: Phase 1 clinical-stage imaging agent developed for MNPR-101 RIT, enabling therapy-associated visualization during clinical assessment
- Early Pipeline Solid Cancers: Early preclinical-stage drug candidates targeting solid cancers, advancing through early preclinical development activities within pipeline
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Monopar Therapeutics
Bellus Health
HQ: Canada
Website
- Description: Provider of drug development for rare diseases, starting with kidney-affecting conditions. Lead program KIACTA, a novel drug candidate, is in data review following top-line results from a Phase 3 study for the treatment of AA amyloidosis, a rare disease resulting in renal dysfunction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bellus Health company profile →
Oncorus
HQ: United States
Website
- Description: Provider of immuno-oncology solutions developing oncolytic viruses to fight cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oncorus company profile →
Alzamend Neuro
HQ: United States
Website
- Description: Provider of biotech therapies for Alzheimer's disease that develops and commercializes drugs, treatments, and cures. Includes AL001, an ionic cocrystal delivering lithium via lithium/proline/salicylate for Alzheimer's, bipolar disorder, major depressive disorder, and PTSD; and ALZN002, a cell-based therapeutic vaccine using a mutant-peptide sensitized cell to restore the patient's immune system's ability to combat Alzheimer's.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alzamend Neuro company profile →
Human Genome Sciences
HQ: United States
Website
- Description: Provider of global healthcare focused on helping people do more, feel better, and live longer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Human Genome Sciences company profile →
Xyphos
HQ: United States
Website
- Description: Provider of CAR-T cell therapy platforms for treating relapsed hematological malignancies and solid tumors. Offers ACCEL, which uses engineered ligands to precisely control activity and targeting of universal convertibleCAR-T with tumor-specific antibodies, and ConvertibleCAR, a technology modifying NKG2D to enable flexible multi-antigen targeting and enhanced immune cell activation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xyphos company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Monopar Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Monopar Therapeutics
2.2 - Growth funds investing in similar companies to Monopar Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Monopar Therapeutics
4.2 - Public trading comparable groups for Monopar Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →